Knowledge, attitude, perceived barriers, and practices among pharmacists regarding risk assessment of cardiovascular disease: a cross-sectional study in Yemen

References

• Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.
   PubMed Web of Science ®Google Scholar
• Organization WH. Prevention of cardiovascular disease: guidelines for assessment and management of total cardiovascular risk. Geneva: World Health Organization; 2007.
   Google Scholar
• Karwalajtys T, Kaczorowski J. An integrated approach to preventing cardiovascular disease: community-based approaches, health system initiatives, and public health policy. Risk Manag Healthc Policy. 2010;3:39–48.
   PubMedGoogle Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2019;74(10):e177–e232.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):e285–e350.
   PubMed Web of Science ®Google Scholar
• Clark D III, Virani SS. 2018 Cholesterol guidelines: key topics in primary prevention. Curr Atheroscler Rep. 2019;21(5):17.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111–188.
   PubMed Web of Science ®Google Scholar
• Hobbs F, Jukema J, Da Silva P, et al. Barriers to cardiovascular disease risk scoring and primary prevention in Europe. QJM. 2010;103(10):727–739.
   PubMed Web of Science ®Google Scholar
• Yeğenoğlu S, Çelikay G. Counselling of pharmacists to community on issues other than drug purchasing and drug related information: a survey in Ankara. Turk J Pharma Sci. 2005;2(2):83–91.
   Google Scholar
• Hanafi S, Poormalek F, Torkamandi H, et al. Evaluation of community pharmacists’ knowledge, attitude and practice towards good pharmacy practice in Iran. J Pharma Care. 2013;1(1):19–24.
   Google Scholar
• Alshehri AA, Jalal Z, Cheema E, et al. Impact of the pharmacist-led intervention on the control of medical cardiovascular risk factors for the primary prevention of cardiovascular disease in general practice: a systematic review and meta-analysis of randomised controlled trials. Br J Clin Pharmacol. 2020;86(1):29–38.
   PubMed Web of Science ®Google Scholar
• Santschi V, Chiolero A, Paradis G, et al. Pharmacist interventions to improve cardiovascular disease risk factors in diabetes: a systematic review and Meta-analysis of randomized controlled trials. Diabetes Care. 2012;35(12):2706–2717.
   PubMed Web of Science ®Google Scholar
• Ripley TL, Adamson PB, Hennebry TA, et al. Collaborative practice model between cardiologists and clinical pharmacists for management of patients with cardiovascular disease in an outpatient clinic. Ann Pharmacother. 2014;48(3):412–419.
   PubMed Web of Science ®Google Scholar
• Jahangard-Rafsanjani Z, Hakimzadeh N, Sarayani A, et al. A community pharmacy-based cardiovascular risk screening service implemented in Iran. Pharm Pract. 2017;15(2):919.
   PubMed Web of Science ®Google Scholar
• Al-Worafi YM. Drug safety in Yemen. Drug safety in developing countries. Cambridge (MA): Elsevier; 2020. p. 391–405.
   Google Scholar
• Daniel WW, Cross CL. Biostatistics: a foundation for analysis in the health sciences. Hoboken (NJ): Wiley; 2018.
   Google Scholar
• Naing L, Winn T, Rusli B. Practical issues in calculating the sample size for prevalence studies. Archiv Orofac Sci. 2006;1:9–14.
   Google Scholar
• Lloyd-Jones DM, Braun LT, Ndumele CE, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology. Circulation. 2019;139(25):e1162–e1177.
   PubMed Web of Science ®Google Scholar
• Pokharel Y, Steinberg L, Chan W, et al. A dataset to assess providers’ knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association cholesterol management guideline. Data Brief. 2016;7:595–598.
   PubMed Web of Science ®Google Scholar
• Zolezzi M, Abdallah O, Aden S, et al. Perceived preparedness of health care students for providing cardiovascular disease risk assessment and management. Pharmacy. 2017;5(4):9.
   Google Scholar
• El Hajj MS, Mahfoud ZR, Al Suwaidi J, et al. Role of pharmacist in cardiovascular disease-related health promotion and in hypertension and dyslipidemia management: a cross-sectional study in the State of Qatar. J Eval Clin Pract. 2016;22(3):329–340.
   PubMed Web of Science ®Google Scholar
• Bucheit JD, Helsing H, Nadpara P, et al. Clinical pharmacist understanding of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. J Clin Lipidol. 2018;12(2):367–374.e3.
   PubMed Web of Science ®Google Scholar
• Zaitoun MF, Iflaifel MH, Almulhim LA, et al. Awareness of physicians and clinical pharmacists about ACC/AHA guidelines for dyslipidemia management: a cross-sectional study. J Pharm Bioallied Sci. 2019;11(2):181–186.
   PubMed Web of Science ®Google Scholar
• Zolezzi M, Abdallah O, Sankaralingam S. Development and evaluation of an educational program for community pharmacists on cardiovascular risk assessment. RMHP. 2020;13:623–632.
   Web of Science ®Google Scholar
• Brinkman DJ, Tichelaar J, van Agtmael MA, et al. Self‐reported confidence in prescribing skills correlates poorly with assessed competence in fourth‐year medical students. J Clin Pharmacol. 2015;55(7):825–830.
   PubMed Web of Science ®Google Scholar
• Zolezzi M, Abdallah O, Kheir N, et al. Evaluation of community pharmacists' preparedness for the provision of cardiovascular disease risk assessment and management services: a study with simulated patients. Res Soc Admin Pharm. 2019;15(3):252–259.
   PubMed Web of Science ®Google Scholar
• Mohamed SS-E, Mahmoud AA, Ali AA. Involvement of Sudanese community pharmacists in public health activities. Int J Clin Pharm. 2013;35(3):393–400.
   PubMed Web of Science ®Google Scholar
• Tanner RM, Safford MM, Monda KL, et al. Primary care physician perspectives on barriers to statin treatment. Cardiovasc Drugs Ther. 2017;31(3):303–309.
   PubMed Web of Science ®Google Scholar
• Awad A, Abahussain E. Health promotion and education activities of community pharmacists in Kuwait. Pharm World Sci. 2010;32(2):146–153.
   PubMedGoogle Scholar
• Toklu H, Akıcı A, Oktay Ş, et al. The pharmacy practice of community pharmacists in Turkey. MPJ. 2010;1(14):53–60.
   Google Scholar
• Albekairy AM. Pharmacists' perceived barriers to patient counseling. J Appl Pharma Sci. 2014;4(1):70.
   Google Scholar
• Bojar I, Sarecka-Hujar B, Owoc J, et al. Self-assessment of polish pharmacy staff's readiness to promote health. Int J Clin Pharm. 2020;42(5):1354–1363.
   PubMed Web of Science ®Google Scholar
• O'Donnell DC, Brown CM, Dastani HB. Barriers to counseling patients with obesity: a study of Texas community pharmacists. J Am Pharm Assoc. 2006;46(4):465–471.
   Google Scholar
• Yang S, Kim D, Choi HJ, et al. A comparison of patients’ and pharmacists’ satisfaction with medication counseling provided by community pharmacies: a cross-sectional survey. BMC Health Serv Res. 2016;16(1):1–8.
   PubMed Web of Science ®Google Scholar
• Alonso-Perales MM, Lasheras B, Beitia G, et al. Barriers to promote cardiovascular health in community pharmacies: a systematic review. Health Promot Int. 2017;32(3):535–548.
   PubMed Web of Science ®Google Scholar
• Laliberté M-C, Perreault S, Damestoy N, et al. Ideal and actual involvement of community pharmacists in health promotion and prevention: a cross-sectional study in Quebec, Canada. BMC Public Health. 2012;12(1):192–111.
   PubMed Web of Science ®Google Scholar
• Ferrante D, Konfino J, Linetzky B, et al. Barriers to prevention of cardiovascular disease in primary care settings in Argentina. Rev Panam Salud Publ. 2013;33(4):259–266.
   PubMed Web of Science ®Google Scholar
• Tawfik MY, Fahim AE, Ismail MA, et al. Barriers to the utilization of cardiovascular risk prediction tools as perceived by primary health care and family physicians. Egypt J Commun Med. 2015;33(1):15–31.
   Google Scholar